Monoclonal antibody capable of recognizing HPV18 and/or HPV45, and applications thereof

An antibody and carrier technology, applied in applications, antibodies, antiviral agents, etc., can solve the problems of uncertain treatment plan, inconsistent interpretation of CIN2, and difficulty in accurate diagnosis.

Inactive Publication Date: 2018-12-18
ATTOGEN BIOMEDICAL SUZHOU INC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current clinical treatment of CIN2 is controversial because of the difficulty in accurate diagnosis and the uncertainty of appropriate treatment options
There is a large degree of variability in the diagnosis of CIN2 between observers, and even in the United States, where the training is strict, there is significant inconsistency in the interpretation of CIN2

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody capable of recognizing HPV18 and/or HPV45, and applications thereof
  • Monoclonal antibody capable of recognizing HPV18 and/or HPV45, and applications thereof
  • Monoclonal antibody capable of recognizing HPV18 and/or HPV45, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0166] Preparation of monoclonal antibodies

[0167] Antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, an antigen of the invention may be administered to an animal to induce the production of monoclonal antibodies. For monoclonal antibodies, hybridoma technology can be used to prepare (see Kohler et al., Nature 256; 495, 1975; Kohler et al., Eur.J.Immunol.6:511, 1976; Kohler et al., Eur.J.Immunol. 6:292,1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981), phage display technology or available recombinant DNA method (US Patent No. 4,816,567).

[0168] Representative myeloma cells are those that fuse efficiently, support stable high-level production of antibody by selected antibody-producing cells, and are sensitive to culture medium (HAT medium matrix), including myeloma cell lines, such as murine Myeloma cell lines, including those derived from MOPC-21 and MPC-1...

Embodiment 1

[0203] 1 Preparation of human papillomavirus HPV18 E7 monoclonal antibody

[0204] 1.1 Animal immunity

[0205] Five 4-6-week-old female BALB / C mice were taken, and the immunogen was His-HPV18 E7 protein. The immunization procedures are shown in Table 1. Before each immunization, the blood was collected by docking the tail of the mice, and the His-HPV18 E7 recombinant protein (5 μg / ml) was used as the detection antigen to coat the indirect ELISA method to detect the serum titer of the mice. The titer titer of the serum of the immunized mice was >1: At 10,000 splenocytes were taken for fusion. Results #F mouse serum had the highest titer and reached the fusion standard ( figure 1 ), and #F mice were taken for fusion.

[0206] Table 1 Mouse immunization program

[0207]

[0208] 1.2 Cell Fusion and Culture

[0209] The splenocytes of immunized mice were collected and fused with myeloma cells SP2 / 0 according to conventional methods. The fusion ratio of splenocytes: SP2 / 0=...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a monoclonal antibody capable of recognizing HPV18 and/or HPV45, and applications thereof. According to the present invention, the monoclonal antibody can highly-specifically detect HPV18 and/or HPV45 E7 oncoprotein in cervical epithelial cancer (precancerous) cells so as to clearly distinguish cervical epithelial canceration (precancerous change) abnormalities caused by persistent infection with HPV18 and/or HPV45, such that the effective auxiliary detection information can be provided for doctors in the accurate diagnosis of relevant cases, the cervical cancerdetection and early intervention can be improved, the missed diagnosis and the clinical over-treatment of relevant cervical canceration can be reduced, and the unnecessary colposcopy can be reduced and avoided.

Description

technical field [0001] The invention belongs to the field of biological diagnosis and medicine, in particular, the invention relates to the identification of (pre)cancerous tumor cells caused by persistent infection of human papillomavirus (HPV) 18 and / or 45, including human cervical epithelial carcinoma (pre) ) monoclonal antibody to cell change and its application in immunohistochemical staining. Background technique [0002] The final diagnosis of cervical cancer (pre) lesions is based on pathological histocytological morphology as the gold standard. The grades of cervical lesions are divided into cervical intraepithelial neoplasia (CIN) (CIN1, CIN2 and CIN3), carcinoma in situ and invasive carcinoma. Among them, low-grade intraepithelial neoplasia CIN1 is the manifestation of acute HPV infection, and the probability of lesions regressing and turning into normal tissues is high. High-grade intraepithelial neoplasia CIN3 has a significant risk of progression to cancer, s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/08C12N15/13C12P21/02A61K39/42A61P31/20A61P35/00G01N33/569G01N33/574
CPCC07K16/084C07K2317/33C07K2317/35C07K2317/92G01N33/56983G01N33/57442G01N2333/025
Inventor 常小迦韩凤丽薛伟民刘岩
Owner ATTOGEN BIOMEDICAL SUZHOU INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap